This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
HOT-HMV 2 was a completed phase 4 study evaluating an observational group of patients with COPD exacerbation. The registry identifies 12 month admission free survival as the primary endpoint.
| Feature | HOT-HMV |
|---|---|
| Title | HOT HMV 2: A Phase 4 Study |
| Status | Completed |
| Condition | COPD Exacerbation |
| Lead sponsor | Guy's and St Thomas' NHS Foundation Trust |
| Sponsor type | Other |
| Intervention | Observational Group (other) |
| Enrollment | 13 |
2. Clinical Question
The registry question addressed whether patients undergoing initiation of non-invasive ventilation after COPD exacerbation could be characterized according to 12 month admission free survival.
Population
Patients with COPD exacerbation enrolled in the phase 4 study.
Intervention / exposure
Observational Group (other).
Comparator
The registry does not identify a comparator group.
Primary question
How many patients were not admitted to hospital during the 12 months following initiation of NIV and still alive.
3. Trial Design
The registry describes an observational group rather than a randomized treatment comparison. As a result, the primary statistical question differs from a conventional randomized controlled trial comparing outcomes between assigned interventions.
4. Endpoints
| Endpoint | Time frame | Registry definition |
|---|---|---|
| 12 month admission free survival | 12 months | How many patients were not admitted to hospital during the 12 months following initiation of NIV and still alive |
5. Planned Analysis
The registry identifies the primary endpoint but does not report posted statistical analyses or outcome estimates.
Admission free survival is a time-to-event type outcome because patients may experience hospital admission or death over follow-up. A typical analysis of this endpoint would account for the timing of events and censoring, often using survival analysis methods such as Kaplan-Meier estimation or related time-to-event approaches depending on the prespecified statistical analysis plan.
The ClinicalTrials.gov record does not report results for this endpoint.
For admission free survival, the event definition must clearly specify whether hospitalization, death, or another outcome determines failure of event-free status.
6. Statistical Methods Explained
How is admission free survival different from simply counting admissions?
A simple admission count ignores timing and may treat an admission occurring shortly after initiation the same as one occurring near the end of follow-up. Time-to-event methods incorporate when events occur.
Why does censoring matter in this type of endpoint?
Some participants may not have complete observation through the entire follow-up period. Survival methods allow available follow-up information to contribute without assuming that missing follow-up automatically represents success or failure.
Why is the sample size important for interpretation?
The enrollment of 13 participants means estimates of admission free survival would be based on a small number of observations. Small studies generally produce greater uncertainty around estimated event rates.
Why is an observational design different from randomization?
Randomization balances measured and unmeasured factors between groups. An observational study describes outcomes in the enrolled population but does not create the same randomized comparison framework.
What would a confidence interval communicate for this endpoint?
A confidence interval would describe uncertainty around an estimated survival probability or related measure. It would not describe the range of outcomes expected for every individual patient.
Why must endpoint definitions be precise?
Admission free survival combines multiple clinical events into one outcome. Statistical interpretation depends on exactly how hospital admission and survival status are defined.
7. Results Availability
Because no outcome estimates, confidence intervals, or p-values are reported in the registry, a treatment-effect estimate or comparative interpretation cannot be derived from the available record.
8. Limitations
- Small enrollment: The study includes 13 participants, limiting statistical precision.
- No comparator reported: The registry describes an observational group rather than a randomized comparison.
- No posted results: ClinicalTrials.gov does not report endpoint estimates or formal analyses.
- Endpoint complexity: Admission free survival requires careful specification of event definitions and censoring rules.
- Generalizability: Results from a specific enrolled population may not represent all patients with COPD exacerbation.
9. Why This Trial Matters Statistically
HOT-HMV provides a useful example of how statistical analysis depends on study design, endpoint construction, and available information. Even without posted results, the trial illustrates several important biostatistical principles.
| Concept | How it appears in HOT-HMV |
|---|---|
| Observational design | Outcomes assessed within an observational group |
| Time-to-event analysis | Admission free survival over 12 months |
| Censoring | Potential consideration for incomplete follow-up |
| Endpoint definition | Hospital admission and survival status combined into a clinical outcome |
| Statistical uncertainty | Small enrollment affects precision of estimates |
10. Related Tutorials
Learn more about the methods used in this trial:
11. Related Calculators
12. Sources
- ClinicalTrials.gov: NCT04272879.
Continue through the Clinical Biostats knowledge graph
Connect clinical trial endpoints with statistical methods, interpretation frameworks, and analysis workflows.
13. Record Summary
HOT-HMV demonstrates the importance of aligning statistical interpretation with study design. The registry identifies a 12 month admission free survival endpoint following initiation of NIV in COPD exacerbation, but the ClinicalTrials.gov record does not report statistical analyses or results. The appropriate interpretation therefore focuses on endpoint methodology, observational design, and the principles required for evaluating time-to-event outcomes.